Hypertension: Renal denervation-promising data from the DENERHTN trial

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Nephrology

Background:

• Resistant hypertension poses a significant challenge in cardiovascular disease management.
• Standardized stepped-care antihypertensive treatment (SSAHT) is the current guideline-recommended approach.
• Previous trials like SYMPLICITY HTN-3 reported mixed results for renal denervation.

Purpose of the Study:

• To evaluate the efficacy of renal denervation in addition to SSAHT for blood pressure reduction.
• To assess the safety and effectiveness of combined therapy in patients with resistant hypertension.

Main Methods:

• A randomized controlled trial design was employed.
• Patients received either renal denervation plus SSAHT or SSAHT alone.
• Blood pressure was monitored rigorously throughout the study period.

Main Results:

• The combination of renal denervation and SSAHT led to a statistically significant reduction in blood pressure compared to SSAHT alone.
• No major adverse events were reported in the renal denervation group.

Conclusions:

• Renal denervation is a viable adjunctive therapy for patients with resistant hypertension.
• These findings suggest a potential resurgence for renal denervation in clinical practice.